Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$99.99
$97.65
$45.50
$100.00
$6.17B0.551.56 million shs107 shs
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$122.21
$123.21
$28.39
$132.54
$4.75B-0.16128,113 shsN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.93
+3.3%
$14.85
$11.51
$21.50
$2.69B0.52100,318 shs38,321 shs
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$172.36
$171.30
$21.83
$172.46
$6.58B1.421.09 million shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00%0.00%0.00%0.00%0.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+3.31%+3.37%+3.78%+24.65%-4.61%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.3216 of 5 stars
2.04.00.00.00.00.01.9
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00
N/AN/AN/A
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.00
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0019.27% Upside
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARNA, CCXI, EIDX, RETA, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$50K123,305.67N/AN/A$10.94 per share9.14
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
$26.69M177.99N/AN/A$4.57 per share26.74
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.41$0.30 per share53.69$4.43 per share3.60
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$23.48M280.05N/AN/A($1.79) per share-96.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/A
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.91N/AN/AN/AN/A8/7/2025 (Estimated)
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
-$311.90MN/A0.00N/AN/AN/A-922.50%-73.39%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/A
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.05
8.59
8.59
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
0.14
11.10
11.10
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.84
3.21
3.19

Institutional Ownership

CompanyInstitutional Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
83.77%
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
81.09%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
31.40%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
2.41%
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
8.30%
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
70.10%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
26.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
44861.66 million60.17 millionOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Eidos Therapeutics, Inc. stock logo
EIDX
Eidos Therapeutics
7038.87 millionN/ANot Optionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
32138.15 million27.93 millionOptionable

Recent News About These Companies

Reta Hendrickson

Media Sentiment Over Time

Top Headlines

View All Headlines
Arena Pharmaceuticals stock logo

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Eidos Therapeutics stock logo

Eidos Therapeutics NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.93 +0.51 (+3.31%)
As of 07/8/2025 04:00 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Reata Pharmaceuticals stock logo

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.